Current Report Filing (8-k)
03 October 2019 - 9:30PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): October 2, 2019
Harrow
Health, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
|
|
001-35814
|
|
45-0567010
|
(State
or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
12264
El Camino Real, Suite 350
San
Diego, CA
|
|
92130
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(858)
704-4040
(Registrant’s
Telephone Number, including Area Code)
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.001 par value per share
|
|
HROW
|
|
The
NASDAQ Capital Market
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (See General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01. Other Events.
On
May 17, 2019, Harrow Health, Inc. (the “Company”) filed a current report on Form 8-K with the Securities and Exchange
Commission disclosing the outcome of a federal jury trial related to a lawsuit filed by Allergan USA, Inc. (“Allergan”)
in the U.S. District Court for the Central District of California (the “Lawsuit”).
On
October 2, 2019, Allergan and the Company filed a joint stipulation to voluntarily dismiss each parties’ respective pending
appeals arising out of the Lawsuit. No economic consideration was exchanged between the parties related to the filing of
the joint stipulation. This formally resolved all pending disputes between the
parties, as well as potential future legal fee expenditures connected to this matter.
The
Company does not expect the outcome of this litigation to materially
change the business plans or future prospects of its wholly-owned subsidiary business, ImprimisRx.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
HARROW
HEALTH, INC.
|
|
|
|
Date:
October 3, 2019
|
By:
|
/s/
Andrew R. Boll
|
|
|
Andrew
R. Boll
|
|
|
Chief
Financial Officer
|
Harrow (NASDAQ:HROW)
Historical Stock Chart
From Apr 2024 to May 2024
Harrow (NASDAQ:HROW)
Historical Stock Chart
From May 2023 to May 2024